Routine Screening of Strongyloides Among Patients With Lymphoma and Efficacy of Targeted Prophylaxis.

in American journal of hematology by Michele D Stanchina, Camila Sacher, Yamila Melendez, Pamela Dudkiewicz, Jose F Camargo, Izidore S Lossos

TLDR

  • The study found that 6% of lymphoma patients had Strongyloides serology, and treating them with ivermectin reduced the risk of complications.
  • The study supports routine screening and prophylaxis in lymphoma patients to prevent treatment-related complications.
  • The findings have implications for the management of lymphoma patients and highlight the importance of considering Strongyloides as a potential comorbidity.

Abstract

A total of 1372 lymphoma patients (980 newly diagnosed and 392 seen in cellular therapy clinic) were screened for Strongyloides serology, detecting IgG in 80 (6%) patients. Only one out of 80 (1.25%) patients diagnosed and treated with ivermectin for Strongyloides developed disseminated strongyloidiasis following chemotherapy treatments, supporting routine screening and prophylaxis in lymphoma patients.

Overview

  • The study aimed to investigate Strongyloides serology in lymphoma patients, with a focus on the efficacy of screening and prophylaxis.
  • The study involved 1372 lymphoma patients, with 980 newly diagnosed and 392 seen in a cellular therapy clinic.
  • The primary objective of the study was to determine the prevalence of Strongyloides serology in lymphoma patients and explore the efficacy of ivermectin treatment.

Comparative Analysis & Findings

  • The study detected IgG in 80 (6%) patients, highlighting the prevalence of Strongyloides serology in lymphoma patients.
  • Only one of the 80 patients diagnosed with Strongyloides and treated with ivermectin developed disseminated strongyloidiasis following chemotherapy treatments.
  • The study supports routine screening and prophylaxis in lymphoma patients to prevent potential treatment-related complications.

Implications and Future Directions

  • The study suggests that routine screening for Strongyloides serology can help identify patients at risk of treatment-related complications.
  • Future studies can explore the optimal protocol for treating Strongyloides in lymphoma patients, including the timing and duration of treatment.
  • The study highlights the importance of considering Strongyloides as a potential comorbidity in lymphoma patients and incorporating it into treatment planning.
Read Full Article